![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
ABSTRACT
Introduction
Ertugliflozin, a sodium-glucose cotransporter-2 inhibitor, seems to improve glycemic control in type 2 diabetes mellitus (T2DM). We aim to evaluate the efficacy of Ertugliflozin across multiple time intervals (18, 26, and 52 weeks) in T2DM patients.
Methods
A literature search was conducted on electronic databases. Data was extracted from eligible studies at both 5 mg and 15 mg doses in monotherapy and as add-on therapy. Cochrane RevMan was used to perform the meta-analysis.
Results
Ertugliflozin, at both 5 mg and 15 mg doses, demonstrated a significant improvement in HbA1c levels at 18 weeks 5 mg [P = 0.00001], 15 mg [P = 0.05], and at 26 weeks in monotherapy 5 mg [P = 0.006], monotherapy 15 mg [P = 0.006], 5 mg as add-on therapy [P = 0.00001], 15 mg add-on therapy [P = 0.00001] respectively. At 52 weeks, the reduction in HbA1c was significant in 15 mg add-on therapy [P = 0.0001]. Additionally, ertugliflozin as an add-on therapy also led to a significant reduction in FPG, body weight, and systolic blood pressure.
Conclusion
Ertugliflozin showed clinical efficacy in improving glycemic control, fasting plasma glucose, body weight, and systolic blood pressure in T2DM patients over the studied time intervals compared to placebo.
Article highlights
Ertugliflozin acts by a new insulin-independent mechanism, which complements the action of the available conventional therapies for diabetes.
Ertugliflozin offers good glycemic control, as evident from the reduction in HbA1c and fasting plasma glucose at different time points. Moreover, it also promotes weight loss, which has an additional benefit for diabetic patients with obesity.
The results of clinical trials on ertugliflozin are convincing enough to affirm the utility of ertugliflozin as an add-on therapy along with conventional drugs for long-term usage.
This meta-analysis adds to the existing evidence on the effectiveness of the long-term administration of Ertugliflozin in the management of T2DM and also highlights the need for larger and more diverse studies to validate its long-term efficacy.
Declaration of interest
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
Author contributions
P Khan designed the study. P Khan and S Venkatesh screened the literature independently. P Khan and S Venkatesh abstracted data and P Mishra and R Parveen cross-checked the data. N Agarwal and S Jain resolved discrepancies in literature screening and data extraction. P Khan and S Venkatesh analyzed the data. P Khan and S Venkatesh drafted the work and N Agarwal revised it critically for important intellectual content and have given final approval of the version published. All authors contributed to the manuscript revision. All authors have read and agreed to the published version of the manuscript.
Reviewer disclosures
Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.
Supplementary Material
Supplemental data for this article can be accessed online at https://doi.org/10.1080/14656566.2023.2279100